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TRANSLATIONAL RELEVANCE   
Prior clinical trials performed in unselected gastroesophageal adenocarcinoma patients failed to 
show survival improvement upon treatment with anti-EGFR therapies. We report the clinical 
activity of EGFR monoclonal antibodies in patients bearing high level (>8 copies) of EGFR gene 
amplification and show that in Patient-derived xenografts the combination of an EGFR mAb and a 
tyrosine kinase inhibitor is significantly more effective and long lasting than mAb monotherapy. 
We also identify mTOR pathway activation as a novel mechanism of resistance to EGFR targeted 
therapy and show that it can be overcome by the combination of EGFR/mTOR inhibitors. These 
findings recognize EGFR as an actionable target in a small but significant subgroup of patients 
bearing EGFR amplification and suggest the combination of a EGFR mAb and a TKI as the most 





Purpose: Gastric and gastroesophageal adenocarcinomas (GEA) represent the third leading cause 
of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of 
patients with advanced GEA is poor. Randomized clinical trials failed to show a significant survival 
benefit in molecularly unselected patients with advanced GEA treated with anti-EGFR agents.  
Experimental Design: We performed analyses on 4 cohorts: IRCC (570 patients), FMI (9397 
patients), COG (214 patients) and INT (206 patients). Preclinical trials were conducted in patient-
derived xenografts (PDXs). 
Results: The analysis of different GEA patient cohorts suggests that EGFR amplification drives 
aggressive behaviour and poor prognosis. We also observed that EGFR inhibitors are active in 
patients with EGFR copy number gain and that co-amplification of other receptor tyrosine kinases 
or KRAS is associated with worse response. Pre-clinical trials performed on EGFR-amplified GEA 
PDX models revealed that the combination of an EGFR monoclonal antibody and an EGFR 
tyrosine kinase inhibitor was more effective than each monotherapy and resulted in a deeper and 
durable response. In a highly EGFR amplified non-responding PDX, where resistance to EGFR 
drugs was due to inactivation of the TSC2 tumor suppressor, co-treatment with the mTOR inhibitor 
everolimus restored sensitivity to EGFR inhibition.  
Conclusions: This study underscores EGFR as a potential therapeutic target in gastric cancer and 
identifies the combination of an EGFR TKI and a monoclonal antibody as an effective therapeutic 
approach. Finally, it recognizes mTOR pathway activation as a novel mechanism of primary 
resistance that can be overcome by the combination of EGFR and mTOR inhibitors.   
 
 





Gastric and gastroesophageal adenocarcinomas (GEA) represent the third leading cause of cancer-
related deaths worldwide. Despite the introduction of novel systemic treatment options, the outcome 
of patients with metastatic gastroesophageal adenocarcinoma (mGEA) is still extremely 
unsatisfactory, with median overall survival (OS) of less than 12 months in most clinical trials (1).  
While the identification of specific molecular subtypes has had profound implications for targeted 
strategies in other malignancies, the same progress has only been partially realized for patients with 
mGEA. Trastuzumab and ramucirumab (targeting HER2 and VEGFR2, respectively) are the only 
approved targeted agents in mGEA (2,3), whereas the promising role of immune checkpoint 
inhibitors (ICIs) such as pembrolizumab and nivolumab still needs to be confirmed by randomized 
clinical trials (RCTs) performed in properly selected patient subgroups. 
The molecular landscape of GEA has been extensively described and the two main molecular 
classifications (4,5) identified a disease subtype characterized by chromosomal instability and 
amplification of receptor tyrosine kinases (RTKs). Epidermal growth factor receptor (EGFR) 
amplification has been reported in 3-5% of GEAs (4,6), while other genetic alterations (such as 
point mutations or translocations) are extremely uncommon. Several EGFR targeting drugs, 
comprising monoclonal antibodies (MoAbs) and tyrosine kinase inhibitors (TKIs), have been 
approved for the treatment of multiple tumor types, including RAS wild-type metastatic colorectal 
cancer, head and neck squamous cell carcinoma and EGFR mutated advanced non-small cell lung 
cancer (7). Conversely, three phase III Randomized Clinical trials evaluating the addition of 
cetuximab, panitumumab or gefitinib to the standard of care in molecularly unselected patients with 
advanced gastric or esophageal adenocarcinomas reported negative results (8-10). On the other 
hand, intriguingly, experimental data obtained in GEA preclinical models showed a positive 
correlation between cetuximab response and high EGFR expression/amplification (11). Consistent 
with these preclinical findings, the association between EGFR copy number gain (CNG) and better 
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OS has been shown by a phase II trial of cetuximab plus FOLFOX chemotherapy in patients with 
mGEA (12). In addition, a pre-specified subgroup analysis of the COG trial showed that patients 
with esophageal and gastroesophageal junction carcinomas bearing EGFR CNG derived a 
significant progression-free survival (PFS), OS and Health-Related Quality of Life (HRQoL) 
benefit from gefitinib compared to placebo, thereby providing the proof-of-concept for EGFR CNG 
as a predictive biomarker of efficacy of EGFR targeted agents (13).  
Here we aimed to investigate the efficacy of several EGFR inhibition strategies in preclinical 
models of EGFR amplified GEAs, to describe the clinical and molecular features of patients with 
EGFR amplified tumors and their responsiveness to EGFR inhibition, and to extensively investigate 
common and potentially novel genomic mechanisms of resistance, with the ultimate goal to 




MATERIALS AND METHODS   
 
Patients  
IRCC: Tumor samples (from gastric and gastroesophageal junction adenocarcinomas) and matched 
normal samples were obtained from patients undergoing surgery in 15 Italian Hospitals: Candiolo 
Cancer institute- FPO, IRCCS (Torino); Ordine Mauriziano Hospital; San Giovanni Battista 
Hospital (Torino); San Luigi Gonzaga Hospital, Orbassano (Torino); Humanitas-IRCCS, Rozzano, 
Milano; San Raffaele Hospital (Milano); Treviglio-Caravaggio Hospital (Bergamo); Brescia 
Hospital; Borgo-Trento Hospital (Verona); Santa Maria delle Scotte Hospital (Siena); Forli’ 
Hospital; Fondazione Macchi Hospital (Varese); Pisa Hospital; Fondazione IRCCS Istituto 
Nazionale dei Tumori (Milano); Ospedale Niguarda  Ca’ Granda (Milano). All patients provided 
written informed consent; samples were collected and the study was conducted under the approval 
of the Review Boards of all the Institutions. The study was done in accordance with the principles 
of the Declaration of Helsinki, the International Conference on Harmonization and Good Clinical 
Practice guidelines and GDPR (General Data Protection Regulation). Clinical and pathologic data 
were entered and maintained in our prospective database. All the samples have been anonymized 
before being shipped to Candiolo. No reference to the patients can be inferred from the histological 
and molecular characterization presented in the work. 
FMI: Tumor samples from patients with GEA were submitted during routine clinical care for CGP. 
Approval for this study, including a waiver of informed consent and a Health Insurance Portability 
and Accountability Act waiver of authorization, was obtained from the Western Institutional 
Review Board (protocol no. 20152817). 
Cell lines and drugs 
293T cells were obtained from ATCC, OE21 from Sigma Aldrich (Saint Luis, MI, USA). The 
genetic identity of the cell lines was confirmed by short tandem repeat profiling (Cell ID, Promega, 
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Madison, WI, USA). Erlotinib and everolimus were purchased from Carbosynth (UK). Cetuximab 
and lapatinib were provided by the Hospital Pharmacy. 
Primary cell cultures and organoids 
GEA primary cells were derived from PDXs as described in(14), while GEA primary organoids 
were obtained as described in (15). The genetic identity of the in vitro-derived material with the 
original tumor has been verified by short tandem repeat profiling (Cell ID, Promega). GTR0078 
cells were used for the in vitro experiments soon after tumor dissociation, as they do not 
permanently grow in culture. 
Western blot analysis and immunoprecipitation  
Cells/organoids were treated with the indicated drugs: lapatinib or erlotinib 100 nM for 2 hours; 
cetuximab 0.5µg/ml for 16 hours. Whole-protein extracts were prepared using Laemmli buffer and 
quantified using the BCA Protein Assay kit (Pierce, Rockford, lL, USA). EGFR 
immunoprecipitation was performed with cetuximab on organoids (stimulated with EGF 100ng/ml 
for 15’, treated or not with erlotinib 100nM for 2h) previously washed out from matrigel with Cell 
Recovery Solution (#354253, Corning, Glendale, AZ, USA) and lysed with EB (Triton 1%, Tris-
HCl pH7.4 20 mM, EDTA pH8 5mM, Glycerol 10%, NaCl 150mM). Primary antibodies: anti-
EGFR (1005:sc-03) and anti-Actin were from Santa Cruz Biotechnology (Inc., Dallas, Texas, 
USA), antibodies against phosphorylated EGFR (Tyr 845), ERK (Thr202/Tyr204), phosphorylated 
AKT (Ser473) (Clone D9E), total AKT, and ERK were from Cell Signaling (MA, USA). Antibody 
against phosphorylated EGFR (Tyr1068) (ab5644) was from Abcam (Cambridge, UK). Antibody 
directed against aa 1172–1186 of human EGFR was described in (16). Antibody anti-EGFR 
extracellular epitope (111.6 antibody) was from Thermo Fisher Scientific (MA, USA). Secondary 
antibodies were from Amersham. Detection was performed with ECL system (Amersham, UK). 
Transfection and transduction procedures 
OE21 cells were transfected with siRNAs using Lipofectamine2000 (Thermo Fisher Scientific). 
Transfection reagents plus siRNAs at final concentration of 20nM were used following standard 
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protocols. Seventy two hours after transfection, cells were lysed and WB performed. TSC2 silencing 
was achieved using SMARTpool ON-TARGETplus siRNA (Dharmacon, Lafayette, CO, USA). 
Lentiviruses were produced as described in (17). OE21 cells were transduced with a pool of 
lentiviral particles containing of four TSC2 silencing shRNAs (Sigma, #40179, #40178, #40454, 
#40455). Cells were selected with puromicin, checked for TSC2 silencing and subcutaneously 
injected in NOD/SCID mice (5*10^
6
  cells/mouse) in SF medium: Matrigel (Corning) 1:1. 
Analyte extraction 
Genomic DNA was isolated using the Blood & Cell Culture DNA Midi Kit (Qiagen, Germany). 
DNA concentrations were quantified using the Qubit Fluorometer (Thermo Fisher Scientific). 
CNV Evaluation by qReal Time PCR 
Quantitative PCR experiments for estimation of EGFR, MET, FGFR2 and KRAS copy number 
variations were performed in triplicates using 2ng total gDNA as a template, with the following 
Human TaqMan Copy Number Assays: for HER2 assay ID Hs02876245_cn, for EGFR assay ID 
Hs04942325_cn, for MET assay ID: Hs04993403_cn, for FGFR2 assay ID Hs01472955_cn, for 
KRAS assay ID Hs06936191 and the TaqMan Copy Number Reference Assay RNase P 4316831 
and GREB1 Hs01738470_cn (Applied Biosystems, Foster City, CA, USA). PCR runs were 
performed with ABI Prism 7900HT (Applied Biosystems). 
AMNESIA panel 
In a case-control study setting, we identified a panel of gene alterations 
(including EGFR/MET/KRAS/PI3K/PTEN mutations and EGFR/MET/KRAS amplifications) able to 
predict primary resistance to trastuzumab therapy in HER2-positive metastatic gastric cancer 
patients (18). We applied the same panel of gene alterations (substituting EGFR 
mutation/amplification with HER2 mutation/amplification) in the context of EGFR driven tumors.  
Phospho- Kinase Array 
Cells were treated with the indicated drugs: lapatinib or erlotinib 100 nM for 2 hours; cetuximab 
0.5µg/ml for 16 hours. The analysis of the phosphorylation profiles of kinases was performed using 
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the Human Phospho-Kinase Antibody Array (R&D Systems, Minneapolis, MN, USA), according to 
manufacturer instructions. Signal quantification was performed using Image Lab 5.2.1 Software 
(BioRad, Hercules, CA, USA). 
PDX generation 
Gastric PDX generation was performed as described in (19). All animal procedures adhered to the 
‘Animal Research: Reporting of In Vivo Experiments’ (ARRIVE) standards and were approved by 
the Ethical Commission of the Candiolo Cancer Institute (Candiolo, Torino, Italy), and by the 
Italian Ministry of Health. 
PDX xenotrials 
PDXs were passaged and expanded for >2 generations until production of a cohort of mice. 
Established and randomized tumors (average volume 250 mm
3
) were treated for the indicated days 
with the following regimens (either single agent or combination): vehicle (saline) per os; cetuximab 
20 mg/Kg, twice weekly ip; lapatinib 100 mg/kg, daily, per os; erlotinib 50 mg/kg, daily, per os; 
everolimus 6 mg/kg, daily, per os. Tumor size was evaluated once-weekly by caliper measurements 
and approximate volume of the mass was calculated using the formula 4/3π(D/2)(d/2)
2
, where d is 
the minor tumor axis and D is the major tumor axis. The response in mice has been evaluated using 
RECIST 1.1-like criteria, i.e. progressive disease (PD): ≥35 % increase from baseline; partial 
response (PR): ≥ 50% reduction from baseline; stable disease (SD): intermediate variations from 
baseline (20). Statistical testing for pharmacological experiment was performed with GraphPAD 
PRISM Software 8.0, using Two-way ANOVA followed by Bonferroni multiple comparisons 
experiments. Statistical significance: ns= not significant; *p <0,05; **p <0,01; ***p <0,001. 
Genomic sequencing 
IRCC samples: DNA extracted from PDX models along with a sample of normal germline DNA 
from each patient were utilized for next generation sequencing. Using standard methods, Illumina 
sequencing libraries were generated and subjected to hybrid capture with a focused targeted bait set 
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of 243 genes selected based upon their alteration in prior studies of gastroesophageal cancer 
(21,22).  
FMI samples: Comprehensive genomic profiling (CGP) was performed in a Clinical Laboratory 
Improvement Amendments (CLIA)-certified, New York State and CAP (College of American 
Pathologists)-accredited laboratory (Foundation Medicine, Inc., Cambridge, MA). In brief, ≥50ng 
DNA was extracted from 40 microns of formalin-fixed, paraffin-embedded (FFPE) tissue blocks 
from 4,337 cases of gastric carcinoma. The samples were assayed by CGP using adaptor-ligation 
and hybrid capture was performed for all coding exons of from 180-395 cancer related genes plus 
select introns from 14-34 genes frequently rearranged in cancer.  Sequencing of captured libraries 
was performed to a mean exon coverage depth of >500X, and resultant sequences were analyzed for 
genomic alterations including mutations (base substitutions, insertions and deletions), copy number 
alterations (focal amplifications and homozygous deletions), and select gene fusions or 
rearrangements, as previously described(23). EGFR amplification was defined as EGFR copy ≥8. 
COG samples: RTK copy numbers were determined using Affymetrix OncoScan® CNV FFPE 
Assay following the manufacturer recommended protocol.  DNA was extracted from  histologically 
confirmed  oesophageal and GEJ adenocarcinomas as described previously(13) and quantified using 
the Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies) following the manufacturer’s 
recommended protocol, using 80ng  for each  case,  normalised to  a concentration 12 ng/μL. Array 
fluorescence intensity data (CEL files), generated by Affymetrix® GeneChip® Command 
Console® (AGCC) Software version 4.0 were processed using OncoScan® Console software 
version 1.1.034 to produce OSCHP files and a set of QC metrics. Features were quantile normalised 
and genome wide allele specific copy number assessed using the Affymetrix TuScan algorithm to 
allow adjustment for both tumor ploidy and nonaberrant cell admixture(24). Genome wide copy 
number variation was assessed across all cases using AffymetrixNexus Express for OncoScan 
(version 3.1.). Significant copy number variation events across the genome were identified using a 
‘Significance Testing for Aberrant Copy number’ (STAC) approach(25).  
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INT samples: Formalin-fixed paraffin-embedded archival tumor tissue blocks obtained prior to any 
treatment were used for the purpose of this study. Next-generation sequencing was performed as in 
(26), to detect gene mutations, whereas EGFR, HER2 and MET status were determined by SISH 
analysis and KRAS GCN gain was assessed by PCR, as previously described in (18). 
Survival analysis 
OS was calculated from the date of enrollment (for the COG trial) or from the date of diagnosis of 
metastatic disease (for the INT dataset) until the date of death or last follow-up for alive patients. 
The OS curves for EGFR amplified vs non-amplified subgroups were calculated with the Kaplan-
Meier method and compared with the log-rank test. Survival analysis for COG was undertaken 
using IBM SPPS statistics 22, further details see(10,13). 
In situ Hybridization and Immunohistochemistry 
EGFR gene status was assessed by bright-field dual-color SISH (Ventana Medical Systems). The 
Colorado scoring system was adopted to classify samples into ISH strata according to the frequency 
of cells with each EGFR gene copy number and referred to the chromosome 7 centromere. EGFR 
SISH-negative cases had no or low genomic gain for EGFR gene copy number (disomy, low 
trisomy, high trisomy, and low polysomy), whereas the distinction between high polysomy and 
gene amplification was defined by the presence of gene clusters only in EGFR-amplified cases. 
EGFR FISH in the COG cohort was performed and scored as described in (13).  
IHC for EGFR was performed using the CONFIRM® anti-EGFR (5B7) rabbit monoclonal primary 
antibody (Ventana Medical Systems, Tucson, AZ) that recognizes the internal domain of EGFR and 
the monoclonal mouse anti human anti-EGFR (E30) antibody (Dako, Glostrup, Denmark) that 
recognizes an external domain of EGFR. IHC was carried out on an automated immunostainer 
(BenchMark Ultra; Ventana Medical Systems) using the Optiview DAB Detection Kit (Ventana 
Medical Systems). IHC for P-EGFR was performed using anti-P-EGFR Y1173 53AS from Cell 




RNA-seq libraries were prepared using the Illumina TruSeq Stranded Total RNA Library Prep Gold 
kit and sequenced generating 75 bp paired-end reads. PDX RNA-seq data were first deconvoluted 
for mouse contamination with Xenome (27) software (version 1.0.1). Non-host reads (those 
classified as “graft”, “ambiguous” or “both”) were then mapped to UCSC hg38 reference genome 
with HISAT2 (28) aligner with default parameters. Gene expression estimate was performed with 





Prevalence of EGFR amplification in GEA patients   
We evaluated EGFR copy number in four different cohorts: 1) a proprietary cohort (IRCC cohort) 
of 570 primary GEAs (real time PCR analysis); 2) the Foundation Medicine Inc. (FMI) dataset of 
4337 gastric and 5060 esophageal/gastroesophageal junction [GEJ] adenocarcinomas 
(comprehensive genomic profiling); 3) the subgroup of 214 patients with esophageal or GEJ 
adenocarcinoma enrolled in the COG trial (NCT01243398) of second-line gefinitib versus 
placebo(10) (fluorescence in-situ hybridization, FISH); 4) the Fondazione IRCCS Istituto Nazionale 
dei Tumori (INT) of Milan dataset of 206 mGEA patients (in-situ hybridization, SISH). In the 
IRCC cohort we identified 44 primary tumors (7.8%) with EGFR CNG (≥4 gene copies), with 10 of 
them (1.8% of all samples) bearing > 8 gene copies (the suggested threshold of biologically 
meaningful amplification in the HER2 and MET context (30)) and 8 of them (1.4% of all samples) 
bearing a heterogeneous EGFR amplification (one tumor area >8 copies and one tumor area ≤ 8 
copies) (Figure 1 and Supplementary Table 1). In the FMI dataset 3.4% of gastric and 7.6% of 
esophageal carcinomas showed EGFR amplification equal or higher than 8 copies, while in the 
COG and INT datasets the frequencies of EGFR amplification were 7.0% and 4.9 %, respectively 
(Figure 1). In both COG and INT cohorts, no significant association between EGFR amplification 
and baseline clinic-pathological characteristics was observed (Supplementary Table 2 and 3). 
 
EGFR amplification drives aggressiveness and poor prognosis in gastroesophageal 
adenocarcinomas  
To investigate if EGFR amplification is associated with poor prognosis of gastroesophageal 
adenocarcinomas, we took advantage of a cohort of pre-treated patients with esophageal and GEJ 
adenocarcinomas enrolled in the COG trial and randomized to placebo (10). Among 102 cases with 
available EGFR FISH status, patients with EGFR amplification had a significantly inferior median 
16 
 
OS compared to those without EGFR amplification (3.1 versus 3.5 months; HR=1.23, 95% CI: 
1.03-1.48; p=0.026; Figure 2A, left panel). All patients with EGFR amplified tumors died within 4 
months. 
Similarly, when focusing on the INT dataset, patients with EGFR amplification had inferior median 
OS as compared to those with EGFR SISH negative tumors (17.0 versus 18.9 months; HR=1.95, 
95% CI: 0.90-4.21; p=0.083; Figure 2A, right panel). These results have been also confirmed in 
primary gastric tumors analyzing the TCGA data, in which tumor EGFR amplification correlated 
with significantly inferior OS and DFS (Figure 2B). 
 
Activity of EGFR inhibitors in patients with EGFR amplified metastatic gastric cancer and 
landscape of primary treatment resistance 
To determine whether patients with EGFR amplified mGEA may respond to EGFR inhibitors and 
to eliminate the potentially confounding effect of the combination with chemotherapy, we focused 
on patients with EGFR amplified mGEA treated at INT with the anti-EGFR monoclonal antibody 
panitumumab as single-agent after failure of standard treatment options. Three patients with EGFR 
amplification confirmed by SISH were identified (Supplementary Figure 1A); their molecular 
profile is summarized in Supplementary Figure 1B and their clinical history is reported in Figure 3. 
Briefly, INT#1 patient had KRAS co-amplified mGEA and showed progressive disease (PD) at the 
first radiological re-assessment; INT#2 had no co-occurring alterations in HER2, MET, KRAS or 
PIK3CA and showed a partial response (PR) lasting 6 months; INT#3 had co-occurring 
heterogeneous KRAS amplification and showed a PR lasting only 10 weeks and followed by rapid 
clinical progression and death. 
To verify if RTK pathway activation is associated with EGFR inhibitor resistance in GEA, we 
investigated the relationship between RTK copy number gain and survival following treatment with 
gefitinib in 12 EGFR FISH positive gastroesophageal adenocarcinomas (7 with amplification and 5 
with high polysomy) of the COG trial. All 12 tumors analyzed had copy number gain (defined as ≥4 
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gene copies) of at least one RTK (HER2, HER3, HER4, MET, FGFR1, FGFR2, FGFR3, FGFR4, 
IGF1R, PDGFR2, VEGFR1, VEGR2 and VEGFR3). We found a significant inverse correlation 
between the extent of co-amplification of the RTKs and OS (Figure 4A). This observation of shorter 
survival following gefitinib treatment with activation of RTKs other than EGFR suggests 
optimizing inhibition of downstream signal transduction pathways could produce durable clinical 
responses. 
To investigate the prevalence of potential genetic predictors of primary resistance to anti-EGFR 
treatment, we interrogated the TCGA dataset for the presence of resistance alterations included in 
our previously published AMNESIA panel (18) among cases with EGFR amplification and showed 
the co-occurrence of other genomic events in 53% of samples (Suppl. Figure 2). Finally, since the 
available in-silico datasets mainly represent a collection of primary GEAs, we investigated the 
prevalence of AMNESIA panel alterations in the 534 samples from EGFR amplified mGEA 
patients included in the FMI dataset. This analysis showed the co-occurrence of other genomic 
events of interest in 186 (35%) samples (Figure 4B).  
 
Dual EGFR blockade is the most effective treatment of EGFR-amplified PDXs  
Future trials might be prompted to re-assess the role of anti-EGFR MoAbs and TKI, either as 
monotherapy or in combination, in GEA molecularly selected patients. As already shown for dual 
HER2 blockade (trastuzumab plus pertuzumab or lapatinib) in HER2-positive breast and colorectal 
cancer (31-33), and despite the partially negative phase III data recently reported with this strategy 
in HER2-positive gastric cancer (34), dual EGFR blockade strategies with an anti-EGFR MoAb 
plus a TKI may be more effective than each drug as monotherapy.    
A large series of human cancer specimens transplanted into mice (Patient-Derived Xenogratfs, 
PDXs) produce a study population that can be randomized for prospective treatment with targeted 
agents and so provide a strong strategy to perform precision medicine preclinical studies. This 
approach brings together the plasticity of preclinical analysis with the informative value of 
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population-based studies. From 570 gastric carcinoma samples (IRCC cohort), we generated a 
multi-level platform of GEA models, comprising 151 PDXs, primary cell lines and organoids (22). 
Despite conflicting evidence on the CNG threshold clearly defining gene amplification, preclinical 
and clinical data obtained from GEA displaying HER2 or MET amplification suggested that the 
clinically relevant threshold is higher than 8 gene copies (30,35). Eleven PDXs harbored at least 4-8 
EGFR copies and 4 PDXs > 8 EGFR copies (Suppl. Figure 3A: GTR0060: ~240 EGFR copies; 
GTR0078: ~700 copies; GTR0110: 12 copies; GTR0511: ~80 copies). These 4 models did not bear 
any other RTKs/KRAS CNV >8 copies (data not shown). SISH analysis and immunohistochemistry 
confirmed uniform EGFR amplification and expression (Suppl. Figure 3B). These PDX models 
were expanded to generate cohorts of mice, in order to evaluate the efficacy of the EGFR moAb 
cetuximab and the TKI erlotinib (EGFR-selective) and lapatinib (dual EGFR/HER2 inhibitor), as 
well as the combination of the moAb with a TKI. The original tumors were serially passaged in 
vivo until six tumor-bearing animals were produced per experimental group. When xenografts 
reached an average volume of ~250 mm
3
, mice were randomized into six independent treatment 
cohorts: (i) vehicle (placebo); (ii) cetuximab; (iii) erlotinib; (iv) lapatinib; (v) cetuximab + 
erlotinib; (vi) cetuximab + lapatinib. Tumor response was evaluated according to RECIST-like 
Criteria (see Methods and Figure Legends). 
As shown in Figure 5A, the GTR0060 PDX (240 EGFR copies) did not exhibit response to either of 
the TKIs used as monotherapy, but showed partial response (PR) upon cetuximab treatment. 
Notably, both the combo (cetuximab + TKI) treatments resulted in a complete response (CR). 
Interestingly, in 4 out of 6 mice in the combo arms, including 3/3 mice treated with erlotinib + 
cetuximab, the tumor mass did not reappear even after more than two months of drug removal 
(Figure 5B). Improved efficacy of the combo treatment was observed at long term also in a second 
model, GTR0110, characterized by a lower EGFR CNG (12 copies), uniformly distributed among 
tumor cells (Suppl. Figure 3B). While neither erlotinib nor lapatinib resulted in a clinical response 
and cetuximab conferred disease stabilization, cetuximab plus TKI combination treatment resulted 
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in a PR (Figure 5C). Moreover, at the end of the experiment, the tumor volume was significantly 
reduced in mice treated with the combination compared with those treated with the moAb alone. 
The xenotrial performed in the GTR0511 PDX (80 EGFR copies) cohort also showed response to 
anti-EGFR treatment. Even though neither cetuximab nor lapatinib monotherapies were effective, 
their combination resulted in a relevant response. Interestingly, in this PDX erlotinib was the only 
effective monotherapy (Figure 5D). To investigate the reason of the differential sensitivity of 
GTR0511 to erlotinib, we analyzed Whole Exome Sequence data but we did not detect EGFR 
alterations (data not shown). On the contrary, RNAseq analysis revealed a ten-fold decrease of the 
number of reads covering the last portion of the receptor (from exon 26 until the end of the mRNA, 
Suppl. Figure 4A). This resulted in the presence of an EGFR protein isoform lacking the C-terminal 
domain, together with an EGFR full length protein. As Kovacs et al. (36)  showed that the loss of 
this portion of the tail, containing Y1068, determines a strong decrease in receptor activation, we 
immunoprecipitated (with an antibody directed against the EGFR extracellular portion) EGFR from 
organoids derived from the three PDXs. As shown in Suppl. Fig. 4B, in GTR0511 EGFR displayed 
only a modest activation, in spite of the high amount of the expressed protein, meaning that the ratio 
between phosphorylated/unphosphorylated receptor is much lower in GTR0511 compared to the 
other amplified models. As predicted by in silico data, two phosphorylated bands were detected 
only in GTR0511, and they were both effectively inhibited by erlotinib. Finally, stronger 
downstream signal blockade in GTR0511 vs GTR0110 and GTR0060 was seen in total cell lysates 
derived from the same organoids. In agreement with previously published data (36) we thus 
hypothesize that the lack of the EGFR C-terminal tail in GTR0511 can be responsible of its 
decreased activation and increased sensitivity to erlotinib treatment.. 
To investigate which pathways were inactivated by the different drugs/drug combinations in cases 
in which the combo resulted in a strongly enhanced response, we took advantage of PDX-derived 
primary cells in which EGFR amplification was maintained (Suppl. Figure 5A). Primary cells were 
treated with cetuximab, erlotinib and lapatinib, alone or in combination. Western blot analysis 
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showed that while lapatinib and erlotinib only slightly affected activation of downstream 
transducers such as AKT, MAPK and S6 (evaluated as read out of the PI3K, RAS/MAPK and 
mTOR pathways, respectively), a partial inhibition was induced by cetuximab. Interestingly, both 
the dual combinations resulted in a strong inhibition of signal transduction (Figure 5E). Phospho-
array analysis of cellular kinases and RTKs confirmed these results but did not identify any other 
kinase specifically inhibited by the combo treatments (Suppl. Figure 5B). These in vitro data 
strongly support the results we obtained in the in vivo experiments where cetuximab induced SD 
while the two combos resulted in a complete and durable response. It is thus likely that when EGFR 
activation is exceptionally intense, the dual blockade with TKI+cetuximab is needed to improve the 
response. 
 
TSC2 inactivation is a mechanism of resistance to EGFR targeted therapies. 
We performed a preclinical trial, similar to those previously described, using the GTR0078 PDX 
harboring ~700 EGFR copies (Suppl. Figure 3). Despite the very high level of EGFR amplification 
we did not observe response to the TKIs, nor to cetuximab or cetuximab + TKI combos (Figure 
6A). To understand the molecular basis for the observed resistance, we sequenced the tumor DNA 
and detected several genomic alterations; among these, we observed a fraction of EGFR gene 
copies displaying a deletion at the 5’ gene portion, thus coding for a protein lacking the 
extracellular portion (Suppl. Figure 6A). Moreover, we also observed two missense TSC2 mutations 
(p.M1300V and p.R1438Q), with an allelic frequency of 0.463 and 0.539, respectively (Figure 6B).  
The TSC2 protein forms a complex with TSC1, a critical negative regulator of mTORC1 
(mammalian target of rapamycin complex 1) which controls anabolic processes to promote cell 
growth (37-39). TSC2 inactivation (due to homozygous mutations or gene loss), results in mTOR 
increased activation (40). Interestingly, when we interrogated cBioPortal for the possible co-
occurrence of EGFR and TSC2 functional genomic alterations in six gastric cancer datasets (4,41-
45), we found a significant correlation (Suppl. Figure 6B). Moreover, alterations in the mTOR 
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pathway co-occurrent with EGFR CNG have been identified in the FMI dataset as well, although 
co-occurrence with EGFR amplification was uncommon (Suppl. Figure 6C).  
To support the causative role of TSC2 in EGFR target therapy resistance, we silenced TSC2 in 
OE21 cells, harboring EGFR gene amplification (46). In in vitro experiments, upon TSC2 silencing, 
we observed the constitutive activation of the mTOR pathway, revealed by the activation of the 
downstream transducer S6, which was maintained even in the presence of anti-EGFR treatment 
(Suppl. Figure 7A). To validate these data in vivo, we transduced OE21 cells with either Ctrl 
shRNA (shC) or a pool of TSC2 shRNAs and we injected them in immunocompromised mice. As 
shown in Suppl. Figure Fig. 7B, shC mice underwent tumor regression in response to EGFR 
blockade, while partially TSC2 silenced tumors experienced only disease stabilization, reinforcing 
the idea that TSC2 silencing impairs the response to anti-EGFR therapy.  
We thus wondered if treatment of GTR0078 tumors with a mTOR inhibitor (such as everolimus) 
could restore sensitivity to EGFR inhibitors. While treatment with everolimus alone did not show 
any clinical efficacy (Suppl. Figure 6D), the combination of everolimus with erlotinib resulted in a 
significant clinical response (Figure 6C). Experiments performed in PDX-derived cells showed that 
while treatment of GTR0078 cells with either EGFR inhibitors or everolimus was unable to block 
mTOR activation, the association of the two drugs resulted in a sustained inhibition of the pathway. 
Indeed, only the concomitant inhibition of the EGFR and mTOR pathway inactivated the 




In unselected patients with advanced gastric/esophageal adenocarcinoma, the addition of an anti 
EGFR antibody to first-line standard chemotherapy failed to show a significant survival benefit in 
two randomized clinical trials (8,9). Similar negative results were also observed when the small 
molecule TK inhibitor gefitinib was compared to placebo from the second-line setting and beyond 
(10).
 
Sporadic responses to EGFR inhibitors observed in these trials, however, lead several 
researchers to postulate the existence of a subset of metastatic patient with EGFR-addicted tumors, 
potentially vulnerable to EGFR blockade (13). The amplification of the EGFR gene is found in 3-
5% of primary GEA tumors (4,6)  and highly correlates with poor prognosis (47). By exploiting 
four different datasets, we have shown here that EGFR amplification has similar prevalence and is 
associated with poorer survival in the metastatic setting. This was also confirmed in the non-
metastatic setting, analyzing the TCGA data.  In a pre-specified exploratory analysis of one of those 
data sets, the COG trial randomizing 209 chemo-resistant metastatic patients to gefitinib or placebo 
(10), EGFR amplification is a positive predictive marker for EGFR targeting, whereas a smaller 
advantage is observed in patients with chromosome 7 polysomy (13). Response to the anti-EGFR 
moAb cetuximab, used alone or in combination with chemotherapy, was reported in a small set of 
seven EGFR amplified patients; albeit the role of the cytotoxic backbone contribution cannot be 
ruled out in three responders, one response was induced by EGFR blockade alone (48). Such results 
clearly mirror those achieved in patients receiving panitumumab monotherapy by our study. All 
together these observations suggest that EGFR is an oncogenic driver, with potentially exquisite 
sensitivity to EGFR targeting drugs, in a small but clinically consistent subgroup of GEAs. On the 
other hand, in these EGFR-amplified tumors, we observed the presence of selected co-occurring 
driver alterations. Specifically MET/HER2/KRAS co-amplifications and KRAS/PK3CA/PTEN co-
mutations were identified in 53% and 35% of patients in the EGFR amplified subgroups included in 
the TCGA and FMI datasets, respectively; this result highlights that only a subset of patients with 
EGFR amplified gastroesophageal cancer may significantly benefit from single-agent anti-EGFR 
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therapy. Here, we have for the first time functionally identified TSC2 mutations as a potential new 
mechanism conferring resistance to EGFR inhibition in GEAs. TSC2 is a GTPase-activating 
protein, whose loss or inactivating mutation result in the constitutive load of Rheb with GTP and 
activation of mTORC signaling (39). Interestingly, according to cBioPortal, TSC1/TSC2 mutations 
are significantly associated with EGFR amplification (but not with other RTKs) in GEAs, possibly 
indicating that mTORC constitutive activation can sustain the oncogenic role of EGFR. Our 
preclinical trial in an EGFR amplified/TSC2 mutated GEA PDX confirms this hypothesis. The 
pharmacological inhibition of TSC2-sustained mTORC activation by everolimus, a clinical grade 
small molecule mTOR inhibitor, overcame primary resistance and restored sensitivity to EGFR 
inhibition. Our data are reinforced by  a recently published paper from Arteaga and coll. (49),  in 
which they showed that hyperactivation of the mTORC pathway drives resistance to therapies 
targeting another member of the HER family, namely HER2, in HER2-mutant breast cancer. In 
their work, similarly to what we have observed, the combination of the TORC1 inhibitor everolimus 
and neratinib overcame resistance.    
Resistance is a common occurrence of RTK inhibition across diseases, targets and drugs. Several 
cell autonomous mechanisms sustaining resistance to driver RTKs have been identified so far, 
including mutations of the target itself, activation of downstream transducers, activation of parallel 
pathways and transdifferentiation. Moreover, in many cases the amplified RTK is not located in the 
natural genomic site, but it is rather extrachromosomal. This results in a mechanism favoring rapid 
adaptation of cancer cells to environmental changes. Indeed, as extrachromosomal DNA lacks 
centromeres, it is unequally segregated during cell division, leading to increased tumor 
heterogeneity and different cellular fitness in diverse contexts. Cancer cells in which oncogenes are 
extrachromosomal can thus become resistant to RTK inhibitors either by increasing the number of 
gene copies (thus titrating the amount of the available inhibitor) or by progressively decreasing the 
number of gene copies. Both the mechanisms are sustained by experimental data. For example, 
Nathanson et al. (50)  showed that glioblastoma cells can become resistant to erlotinib, eliminating 
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extrachromosomal copies of the mutant EGFR gene. This “adaptation” to the treatment can be 
acquired and expanded along tumor evolution, enabling tumors to maintain their intratumoral 
heterogeneity. In previous works (51,52) we have shown that in MET hyper amplified gastric cancer 
cells (where the amplified gene was extrachromosomal) resistance was due to further acquisition of 
gene copies; this resulted in an amount of activated receptor overcoming the inhibitory ability of the 
drugs at tolerable doses.   
To bypass primary and prevent secondary resistance to EGFR-targeted drugs in EGFR amplified 
GEAs we leveraged our large platform of 151 primary GEAs patient-derived mouse avatars (22), 
enriched for 15 cases with EGFR gene copy gain, including 4 avatars with more than 8 EGFR 
copies (confirmed as amplified -i.e. non polysomic- by silver in situ hybridization). EGFR 
inhibition, in absence of chemotherapy, resulted in a clinical response in three out of four cases. 
Notably, one of these cases featured 12 EGFR copies, a range of amplification that is just above the 
threshold (8 copies) considered biologically relevant and that has not been investigated previously 
(48). Interestingly, a complete response was achieved only in the PDX with the highest EGFR 
CNG, suggesting that a higher level of gene amplification may be associated with a greater 
magnitude of treatment benefit, as it is known for HER2-amplified GEA and breast cancer (30,53).  
The pharmacological space of EGFR targeted drugs is well populated by antibodies and small 
molecule TKIs, both experimental and approved for use in clinically diverse settings (54,55).   
In our preclinical trials in EGFR-amplified GEA avatars we compared the efficacy of randomly 
allocated TKIs and cetuximab, delivered as single agent or in combinations. Erlotinib and 
cetuximab showed single agent excellent activity in one and two models respectively, while in a 
third model cetuximab treatment resulted in disease stabilization. Importantly however, the dual 
EGFR blockade resulted in a sustained significant response in all three models suggesting that a 
strong inhibition of the downstream transducers is needed to eradicate the disease.  
In conclusion, our study further corroborates EGFR amplification as an actionable therapeutic target 
in GEA, demonstrates that a dual EGFR blockade may be needed to maximize the therapeutic 
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efficacy, and identifies potential mechanisms of primary resistance, specifically the mTORC 
pathway, paving the way for experimentally driven clinical trials. In fact, the next generation 
clinical trial landscape in EGFR amplified GEAs may not be at a dead end. The combination of 
lapatinib and cetuximab has already been proven safe in a phase 1 trial (56), potent second-
generation antibodies mixtures against different, non-overlapping epitopes of EGFR – such as 
Sym004 and MM-151 (57,58) – are into clinical development and the TORC pathway is targetable 
with commercially available drugs. Given the diversity of clinically relevant genomic alterations 
and lack of benefit from EGFR targeted therapies in unselected GEA populations, broad based 
genomic profiling is thus necessary to reliably detect EGFR gene amplification in addition to other 
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Figure 1. EGFR copy number gain. The graphs illustrate the percentage of tumors displaying 
EGFR copy number gain (CNG) in four different cohorts. Real time PCR analysis of IRCC 
gastric/gastroesophageal junction (GEJ) adenocarcinomas displaying EGFR gain (4-8 copies or 
more than 8 copies) or heterogeneity (significantly different EGFR CNG in diverse analyzed 
samples from the same tumor, with one tumor sample >8 copies and one tumor sample ≤ 8 copies). 
Comprehensive genomic profiling of FMI gastric and esophageal/GEJ cases, FISH analysis of COG 
esophageal/GEJ cases and SISH analysis of INT gastric/GEJ adenocarcinomas. 
Figure 2. Survival analysis of patients with EGFR CNG. (A) The graphs show the cumulative 
survival (Cum Survival) of patients of the COG (left) and INT (right) cohorts related to EGFR 
CNG. (B) The graphs show the overall survival (left) and the disease-free survival (right) of patients 
of the gastroesophageal TCGA dataset, related to EGFR CNG. 
Figure 3. Clinical history of patients treated with EGFR-targeted drugs. Summarized clinical 
course of INT patients with EGFR CNG. Red-lined boxes indicate periods of administration of the 
indicated therapeutic agents. Blue vertical lines indicate timing of tumor specimen acquisition from 
surgical procedures or biopsies, as well as dates of tumor assessment by CT scan. PD, progressive 
disease; SD, stable disease, according to RECIST 1.1. EOX: epirubicin, oxaliplatin and 
capecitabine; 5FU: 5 fluorouracil; TCF: docetaxel, carboplatin and 5-fluorouracil; FOLFIRI: folinic 
acid, 5-fluorouracil, irinotecan; XELOX: capecitabine and oxaliplatin; CCDP: cisplatin,  
vinorelbine, ifosfamide and epirubicin; OGD: oesophago-gastro-duodenoscopy. 
Figure 4.  RTK/KRAS pathway activation in EGFR amplified cases. (A) The scatter plot shows 
a significant inverse correlation between the extent of RTKs co-amplification (HER2, HER3, HER4, 
MET, FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, PDGFR2, VEGFR1, VEGR2 and VEGFR3 ≥4 
gene copies) and OS in 12 EGFR FISH positive GEAs treated with gefitinib in the COG trial. Red 
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dots indicate cases with high polisomy; blue dots represent cases with EGFR amplification. (B) The 
graph shows the co-occurrence of EGFR amplification and genomic events affecting the 
RTK/KRAS pathway in EGFR amplified GEA tumors in the FMI dataset.    
Figure 5. Dual EGFR blockade is the most effective treatment in EGFR-amplified PDXs 
Tumor growth curves in mice cohorts derived from GTR0060 (A), GTR0110 (C) and GTR0511 (D) 
patients treated with the EGFR inhibitors cetuximab (CETUX), erlotinib (ERL), lapatinib (LAP), 
alone or in combination, as indicated. The red lines indicate the day when treatment was started. 
The response in mice has been evaluated using RECIST 1.1-like criteria, i.e. progressive disease 
(PD): ≥35 % increase from baseline; partial response (PR): ≥ 50% reduction from baseline; stable 
disease (SD): intermediate variations from baseline. (B) Spaghetti plot illustrating drug response 
in the xenotrial performed on the cohort of mice derived from PDX GTR0060. Individual lines 
represent, for each mouse, the percentage variation in tumor burden, from treatment start (day 0). 
Blue lines: CETUX + LAP treated mice; red lines: CETUX + ERL treated mice. Dashed line 
indicates treatment stop. (E) Western blot analysis of the activation state of EGFR and its 
downstream targets (AKT, MAPK and S6) in GTR0060 tumor-derived cells treated with the 
indicated drugs/drug combinations. Actin was used as loading control.  Statistical significance is 
indicated **<0.01; ***<0.001 
Figure 6. TSC2 inactivation is a mechanism of resistance to EGFR targeted therapies. 
(A) Tumor growth curves in the mice cohorts derived from GTR0078 treated with the EGFR 
inhibitors cetuximab (CETUX), erlotinib (ERL), lapatinib (LAP), alone or in combination, as 
indicated. The arrow indicates the day when treatment was started. (B) The table shows the two 
TSC2 mutations identified in GTR0078 PDX. (C) Tumor growth curves in the mice cohorts derived 
from GTR0078 treated with erlotinib (ERL) or the combo erlotinib + everolimus (ERL+ EVEROL). 
The red line indicates the day when treatment was started. (D)  Western blot analysis of the 
activation state of EGFR and its downstream targets (AKT, MAPK and S6) in GTR0078 tumor-
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derived cells treated with the indicated drugs/drug combinations. Actin was used as loading 





1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and 
mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 
2015;136(5):E359-86 doi 10.1002/ijc.29210. 
2. Corso S, Giordano S. How Can Gastric Cancer Molecular Profiling Guide Future Therapies? Trends 
Mol Med 2016;22(7):534-44 doi 10.1016/j.molmed.2016.05.004. 
3. Raimondi A, Nichetti F, Peverelli G, Di Bartolomeo M, De Braud F, Pietrantonio F. Genomic markers 
of resistance to targeted treatments in gastric cancer: potential new treatment strategies. 
Pharmacogenomics 2018;19(13):1047-68 doi 10.2217/pgs-2018-0077. 
4. Network CGAR. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 
2014;513(7517):202-9 doi 10.1038/nature13480. 
5. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric 
cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21(5):449-56 
doi 10.1038/nm.3850. 
6. Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, et al. Genomic Profiling of 
Small-Bowel Adenocarcinoma. JAMA Oncol 2017;3(11):1546-53 doi 10.1001/jamaoncol.2017.1051. 
7. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus 
chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label 
randomised phase III trial. Lancet 2009;373(9674):1525-31 doi 10.1016/S0140-6736(09)60569-9. 
8. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or 
without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a 
randomised, open-label phase 3 trial. Lancet Oncol 2013;14(6):490-9 doi 10.1016/S1470-
2045(13)70102-5. 
9. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Frances A, et al. Epirubicin, oxaliplatin, 
and capecitabine with or without panitumumab for patients with previously untreated advanced 
31 
 
oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 
2013;14(6):481-9 doi 10.1016/S1470-2045(13)70096-2. 
10. Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, et al. Gefitinib for 
oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, 
placebo-controlled randomised trial. Lancet Oncol 2014;15(8):894-904 doi 10.1016/S1470-
2045(14)70024-5. 
11. Zhang L, Yang J, Cai J, Song X, Deng J, Huang X, et al. A subset of gastric cancers with EGFR 
amplification and overexpression respond to cetuximab therapy. Sci Rep 2013;3:2992 doi 
10.1038/srep02992. 
12. Huang J, Fan Q, Lu P, Ying J, Ma C, Liu W, et al. Icotinib in Patients with Pretreated Advanced 
Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: 
A Single-Arm, Multicenter Phase 2 Study. J Thorac Oncol 2016;11(6):910-7 doi 
10.1016/j.jtho.2016.02.020. 
13. Petty RD, Dahle-Smith A, Stevenson DAJ, Osborne A, Massie D, Clark C, et al. Gefitinib and EGFR 
Gene Copy Number Aberrations in Esophageal Cancer. J Clin Oncol 2017;35(20):2279-87 doi 
10.1200/JCO.2016.70.3934. 
14. Apicella M, Migliore C, Capelôa T, Menegon S, Cargnelutti M, Degiuli M, et al. Dual MET/EGFR 
therapy leads to complete response and resistance prevention in a MET-amplified 
gastroesophageal xenopatient cohort. Oncogene 2016 doi 10.1038/onc.2016.283. 
15. Miyoshi H, Stappenbeck TS. In vitro expansion and genetic modification of gastrointestinal stem 
cells in spheroid culture. Nat Protoc 2013;8(12):2471-82 doi 10.1038/nprot.2013.153. 
16. Sigismund S, Algisi V, Nappo G, Conte A, Pascolutti R, Cuomo A, et al. Threshold-controlled 




17. Corso S, Migliore C, Ghiso E, De Rosa G, Comoglio PM, Giordano S. Silencing the MET oncogene 
leads to regression of experimental tumors and metastases. Oncogene 2008;27(5):684-93 doi 
10.1038/sj.onc.1210697. 
18. Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, et al. Biomarkers of Primary 
Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-
Control Study. Clin Cancer Res 2018;24(5):1082-9 doi 10.1158/1078-0432.CCR-17-2781. 
19. Corso S, Cargnelutti M, Durando S, Menegon S, Apicella M, Migliore C, et al. Rituximab Treatment 
Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts. Neoplasia 2018;20(5):443-
55 doi 10.1016/j.neo.2018.02.003. 
20. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of 
patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in 
cetuximab-resistant colorectal cancer. Cancer Discov 2011;1(6):508-23 doi 10.1158/2159-8290.CD-
11-0109. 
21. Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, et al. Genomic Heterogeneity as a 
Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 2018;8(1):37-48 
doi 10.1158/2159-8290.CD-17-0395. 
22. Corso S, Isella C, Bellomo SE, Apicella M, Durando S, Migliore C, et al. A comprehensive PDX gastric 
cancer collection captures cancer cell intrinsic transcriptional MSI traits. Cancer Res 2019 doi 
10.1158/0008-5472.CAN-19-1166. 
23. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and 
validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. 
Nat Biotechnol 2013;31(11):1023-31 doi 10.1038/nbt.2696. 
24. Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy 




25. Diskin SJ, Eck T, Greshock J, Mosse YP, Naylor T, Stoeckert CJ, et al. STAC: A method for testing the 
significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res 
2006;16(9):1149-58 doi 10.1101/gr.5076506. 
26. Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, et al. Negative Hyperselection 
of Patients With. J Clin Oncol 2019:JCO1901254 doi 10.1200/JCO.19.01254. 
27. Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, Williams ED, et al. Xenome--a tool for 
classifying reads from xenograft samples. Bioinformatics 2012;28(12):i172-8 doi 
10.1093/bioinformatics/bts236. 
28. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat 
Methods 2015;12(4):357-60 doi 10.1038/nmeth.3317. 
29. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing 
data. Bioinformatics 2015;31(2):166-9 doi 10.1093/bioinformatics/btu638. 
30. Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, et al. Level of HER2 gene 
amplification predicts response and overall survival in HER2-positive advanced gastric cancer 
treated with trastuzumab. J Clin Oncol 2013;31(35):4445-52 doi 10.1200/JCO.2013.48.9070. 
31. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant 
Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017;377(2):122-
31 doi 10.1056/NEJMoa1703643. 
32. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel 
for metastatic breast cancer. N Engl J Med 2012;366(2):109-19 doi 10.1056/NEJMoa1113216. 
33. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and 
docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372(8):724-34 doi 
10.1056/NEJMoa1413513. 
34. Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and 
chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): 
34 
 
final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 
2018;19(10):1372-84 doi 10.1016/S1470-2045(18)30481-9. 
35. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and 
complementary role of MET amplification and EGFR T790M mutation in acquired resistance to 
kinase inhibitors in lung cancer. Clin Cancer Res 2010;16(22):5489-98 doi 10.1158/1078-0432.CCR-
10-1371. 
36. Kovacs E, Das R, Wang Q, Collier TS, Cantor A, Huang Y, et al. Analysis of the Role of the C-Terminal 
Tail in the Regulation of the Epidermal Growth Factor Receptor. Mol Cell Biol 2015;35(17):3083-102 
doi 10.1128/MCB.00248-15. 
37. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses 
mTOR signalling. Nat Cell Biol 2002;4(9):648-57 doi 10.1038/ncb839. 
38. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 
and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-
mediated downstream signaling. Proc Natl Acad Sci U S A 2002;99(21):13571-6 doi 
10.1073/pnas.202476899. 
39. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends 
Biochem Sci 2004;29(1):32-8 doi 10.1016/j.tibs.2003.11.007. 
40. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, et al. Pathogenesis of 
tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 
leads to mTOR activation. J Neuropathol Exp Neurol 2004;63(12):1236-42 doi 
10.1093/jnen/63.12.1236. 
41. Chen K, Yang D, Li X, Sun B, Song F, Cao W, et al. Mutational landscape of gastric adenocarcinoma in 




42. Guo YA, Chang MM, Huang W, Ooi WF, Xing M, Tan P, et al. Mutation hotspots at CTCF binding 
sites coupled to chromosomal instability in gastrointestinal cancers. Nat Commun 2018;9(1):1520 
doi 10.1038/s41467-018-03828-2. 
43. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing and comprehensive 
molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014;46(6):573-82 
doi 10.1038/ng.2983. 
44. Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function 
mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 2014;46(6):583-7 doi 
10.1038/ng.2984. 
45. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent 
mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011;43(12):1219-23 doi 
10.1038/ng.982. 
46. Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M, et al. CDK4/6 or MAPK blockade 
enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun 
2017;8:13897 doi 10.1038/ncomms13897. 
47. Chen C, Yang JM, Hu TT, Xu TJ, Yan G, Hu SL, et al. Prognostic role of human epidermal growth 
factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res 
2013;44(5):380-9 doi 10.1016/j.arcmed.2013.07.001. 
48. Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, et al. Targeted Therapies for Targeted 
Populations: Anti-EGFR Treatment for. Cancer Discov 2018;8(6):696-713 doi 10.1158/2159-
8290.CD-17-1260. 
49. Sudhan DR, Guerrero-Zotano A, Won H, Ericsson PG, Servetto A, Huerta-Rosario M, et al. 
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in 
HER2-Mutant Cancers. Cancer Cell 2020;37(2):258-9 doi 10.1016/j.ccell.2020.01.010. 
36 
 
50. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, et al. Targeted therapy resistance 
mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 
2014;343(6166):72-6 doi 10.1126/science.1241328. 
51. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, et al. MET and KRAS gene amplification 
mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010;70(19):7580-90 
doi 10.1158/0008-5472.CAN-10-0436. 
52. Martin V, Corso S, Comoglio PM, Giordano S. Increase of MET gene copy number confers resistance 
to a monovalent MET antibody and establishes drug dependence. Mol Oncol 2014 doi 
10.1016/j.molonc.2014.06.010. 
53. Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, et al. A combinatorial 
biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab 
without chemotherapy in patients with HER2+ breast cancer. Ann Oncol 2019 doi 
10.1093/annonc/mdz076. 
54. Moradi-Kalbolandi S, Hosseinzade A, Salehi M, Merikhian P, Farahmand L. Monoclonal antibody-
based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan 
HER. J Pharm Pharmacol 2018;70(7):841-54 doi 10.1111/jphp.12911. 
55. Singh D, Attri BK, Gill RK, Bariwal J. Review on EGFR Inhibitors: Critical Updates. Mini Rev Med Chem 
2016;16(14):1134-66 doi 10.2174/1389557516666160321114917. 
56. Deeken JF, Wang H, Subramaniam D, He AR, Hwang J, Marshall JL, et al. A phase 1 study of 
cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer 
2015;121(10):1645-53 doi 10.1002/cncr.29224. 
57. Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, et al. Enhanced Targeting 
of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic. Mol Cancer 
Ther 2015;14(7):1625-36 doi 10.1158/1535-7163.MCT-14-0772. 
37 
 
58. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. Sym004: a novel synergistic 
anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer 
Res 2010;70(2):588-97 doi 10.1158/0008-5472.CAN-09-1417. 
 






